Abgenix, Inc. (ABGX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (257)	7/16/2003 8:17:35 PM
From: Icebrg	Read Replies (2) of 590

>> They did not say is this second antibody for second target or new antibody for old target. What is going on with first antibody?>> Everything is possible. The first IND was filed in October 2000. That is two and a half years ago. Enough time to realise a product failure and start over again. However... The original agreement from 1997 provided for three targets. This agreement was expanded in February 2000 to include two additional antibody product candidates. And in January 2001 there was a further expansion/extension to include an additional 10 candidates. All in all 15 at that time. It appears as if Pfizer in the beginning of January 2001 felt that 5 different antibodies was not enough. And if they had 4 or 5 under pre-clinical development already two and a half years ago, I think it is more probable that it is a new target they are talking about. Would they btw. be able to collect a new milestone if it was the same target (i.e. a back-up mAb replacing a failed one). Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next